Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
OBJECTIVES:
I. Determine the safety and efficacy of a short course (72 hours) of intravenous
acetylcysteine in patients with acute liver failure for whom no antidote or specific
treatment is available.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborators:
University of Texas University of Texas Southwestern Medical Center